An index created at The University of Texas MD Anderson Cancer Center in Houston, based on protein biomarkers was able to discriminate between women at high risk and low risk for ovarian cancer recurrence, in a recent analysis. Such information can be used to help improve the treatment and, eventually, the prognosis of patients with ovarian cancer, who are at high risk for tumor recurrence. Read full article here.
Related Topics
OCRA Sponsors NCCN Guidelines for Ovarian Cancer and Cervical Cancer Patients
This article was updated in July 2024 to reflect NCCN’s release of the 2024 Guidelines for Ovarian Cancer Patients. OCRA is a proud sponsor of NCCN’s 2024 Ovarian Cancer Updates … Continued
OCRA’s 2024 Grantees: Mentored Investigator Grants
OCRA’s 2024 Mentored Investigator Grants are supporting fresh perspectives and approaches to end ovarian and related gynecologic cancers. This year’s grants are awarded to 5 exceptional young researchers who are … Continued
OCRA’s 2024 Grantees: Early Career Investigator Grants
OCRA’s 2024 Early Career Investigator Grants are awarded to 8 outstanding young researchers with a strong commitment to ending ovarian and related gynecologic cancers. These grants fund innovative projects, and … Continued